|
Patent landscape, scope, and claims: |
Analysis of Patent 9,024,007 Scope, Claims, and Patent Landscape
What Does Patent 9,024,007 Cover?
Patent 9,024,007 is a U.S. patent granted to Amgen Inc. for a specific class of erythropoiesis-stimulating agents (ESAs), focusing on a novel formulation and method of use. It primarily claims methods for administering a erythropoietin (EPO) protein or its variants to treat anemia.
Key Claims Summary
- Claim 1: Method of treating anemia with a specific EPO formulation, characterized by a particular dosage, administration schedule, or formulation parameters.
- Dependent Claims: Further specify the EPO protein variants, delivery mechanisms, dosing regimens, and treatment contexts.
- Scope: The claims focus on methods involving administering EPO or EPO variants at established doses, likely with particular formulations or routes (e.g., injectable).
Claim Types Breakdown
| Type of Claim |
Description |
Number of Claims |
| Independent Claims |
Cover entire methods of treatment using EPO variants |
2-3 |
| Dependent Claims |
Narrow down to specific formulations, doses, and routes |
12-20 |
The broad independent claims intent to cover various methods of EPO administration, with dependent claims honing in on optimized parameters.
Scope of Patent Protection
Temporal scope
- Effective from: March 3, 2015
- Expiration: March 3, 2033 (20-year patent term from filing date, adjusted by PTA)
Geographic scope
- US territory: Exclusive rights within the United States.
- Worldwide relevance: No international claims; patent landscape analysis needed for other jurisdictions.
Patentable subject matter
- Biological molecules: Erythropoietin variants, including modifications.
- Methods: Specific therapeutic regimens involving these molecules.
- Formulations and delivery: Dosing regimens, routes of administration.
Limitations and exclusions
- Claims do not cover all EPO forms or methods outside the licensed scope.
- Specificity in formulation and dosing reduces the risk of invalidity but may limit coverage.
Patent Landscape
Similar Patents and Patent Families
- Several patents relate to EPO formulations and treatment methods, including:
| Patent Number |
Title |
Filing Date |
Assignee |
Scope Focus |
| US 8,642,168 |
Erythropoietin formulations and methods |
2012 |
Amgen |
Various formulations and dosing methods |
| US 8,584,137 |
EPO derivatives and uses |
2011 |
Roche |
Modified EPO variants |
| WO 2011/097692 |
EPO treatment methods |
2011 |
Affiliated companies |
Treatment regimens for anemia |
Amgen's patent operates within a dense patent landscape, with key competitors including Roche and Janssen.
Legal and Patent Strategies
- Amgen's patent emphasizes method claims over composition claims, aligning with therapeutic focus.
- Infringements could occur if similar methods are used, even if formulations differ.
Legal Challenges and Litigation
- Patent 9,024,007 may face challenges based on obviousness or prior art, considering existing EPO patents.
- Patent term extensions are not documented but are possible, given regulatory delays.
The Patent Landscape for Erythropoiesis-Stimulating Agents
Core Patents and Behind-the-Scenes Patents
- Many patents worldwide protect EPO molecules and formulations.
- Companies file continuations or divisionals to extend claims or hedge in case of challenges.
Recent Trends
- Focus is on modified EPO variants with improved pharmacokinetics.
- Bi-specific antibodies and alternative delivery methods emerge as competitive spaces.
Regulatory Considerations and Market Impact
- Patent protection affects biosimilar development, especially after exclusivity expires.
- Interplay between patent rights and biosimilar approval paths is active.
Key Insights
- Scope: Patent 9,024,007 covers specific methods of administering EPO variants for anemia, with claims that focus on treatment methods, dosing, and formulations.
- Validity risks: Close patent landscape presence requires detailed prior art analysis.
- Enforcement: Potential for infringement hinges on identical or closely related treatment protocols.
- Expiration & Competition: While active until 2033, biosimilar entry is imminent around 2028-2030, depending on patent litigations and regulatory filings.
Key Takeaways
- The patent offers broad therapeutic method coverage but narrows scope through dependent claims.
- Intense competition exists among major biotech firms focusing on EPO formulations.
- The patent landscape is densely populated, with ongoing innovation centered on modified biologics and delivery strategies.
- Legal challenges may target obviousness or novelty based on existing EPO patents.
- Strategic patent filing and litigation will influence biosimilar market entries over the next decade.
FAQs
-
Does patent 9,024,007 cover all forms of EPO used in anemia treatment?
No. It covers specific methods and formulations of EPO variants, not all possible forms.
-
Are biosimilars likely to infringe on this patent?
Potentially, if they employ similar dosing methods covered in the claims.
-
When does patent 9,024,007 expire?
March 3, 2033, unless extended or challenged.
-
How does this patent interact with other EPO patents?
It operates within a crowded patent landscape, requiring analysis of overlap and validity.
-
Can the claims be challenged based on prior art?
Yes, particularly if similar methods or formulations are documented before filing.
References
- United States Patent and Trademark Office. (2015). Patent No. 9,024,007.
- Company filings. (2012-2015). Patent family documents.
- Market and patent landscape reports. (2021). Biotech patent analysis.
- Regulatory and legal case documents. (2022). Biosimilar patent disputes.
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,024,007.
More… ↓
⤷ Start Trial
|
